Bristol-Myers Squibb Co. (BMY)
Common Stock Valuation Ratios (Price Multiples)
Beginner level
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
Bristol-Myers Squibb Co., current price multiples
| Bristol-Myers Squibb Co. | Abbott Laboratories | AbbVie Inc. | Allergan PLC | Amgen Inc. | Biogen Inc. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. | Zoetis Inc. | Pharmaceuticals & Biotechnology | Health Care | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||
| Current share price (P) | $63.70 | |||||||||||||||
| No. shares of common stock outstanding | 1,629,284,798 | |||||||||||||||
| Growth rate (g) | -5.66% | |||||||||||||||
| Earnings per share (EPS) | $3.02 | |||||||||||||||
| Next year expected EPS | $2.85 | |||||||||||||||
| Operating profit per share | $3.14 | |||||||||||||||
| Sales per share | $13.85 | |||||||||||||||
| Book value per share (BVPS) | $8.61 | |||||||||||||||
| Valuation Ratios (Price Multiples) | ||||||||||||||||
| Price to earnings (P/E) | 21.09 | 66.91 | 21.85 | — | 15.78 | 11.45 | 41.09 | 14.80 | 25.59 | 35.24 | 19.93 | 15.25 | 27.88 | 45.35 | 27.05 | 28.98 |
| Price to next year expected earnings | 22.36 | 65.19 | 20.51 | — | 14.52 | 8.76 | 39.57 | 10.49 | 31.90 | 36.25 | 19.20 | 13.06 | 35.83 | 32.97 | 25.40 | 27.01 |
| Price to operating profit (P/OP) | 20.28 | 43.41 | 19.47 | — | 12.91 | 8.61 | 35.69 | 9.85 | 19.77 | 26.41 | 15.87 | 14.70 | 92.05 | 35.72 | 21.87 | 22.61 |
| Price to sales (P/S) | 4.60 | 5.18 | 3.79 | 3.93 | 5.88 | 3.77 | 5.41 | 3.73 | 4.80 | 5.18 | 4.14 | 5.55 | 19.18 | 11.12 | 4.88 | 3.83 |
| Price to book value (P/BV) | 7.40 | 5.19 | — | 0.95 | 10.60 | 3.89 | 13.51 | 3.78 | 6.55 | 8.21 | 3.51 | 4.26 | 13.18 | 29.64 | 5.69 | 5.35 |
Based on: 10-K (filing date: 2019-02-25).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Bristol-Myers Squibb Co., historical price multiples
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Bristol-Myers Squibb Co.’s P/E ratio increased from 2016 to 2017 but then decreased significantly from 2017 to 2018. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Bristol-Myers Squibb Co.’s P/OP ratio increased from 2016 to 2017 but then decreased significantly from 2017 to 2018. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Bristol-Myers Squibb Co.’s P/S ratio increased from 2016 to 2017 but then decreased significantly from 2017 to 2018. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Bristol-Myers Squibb Co.’s P/BV ratio increased from 2016 to 2017 but then slightly decreased from 2017 to 2018 not reaching 2016 level. |
Price to Earnings (P/E)
Bristol-Myers Squibb Co., historical P/E calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 1,632,675,877 | 1,632,582,502 | 1,672,715,340 | 1,669,459,090 | 1,662,118,446 | |
| Selected Financial Data (US$) | ||||||
| Net earnings attributable to BMS (in millions) | 4,920 | 1,007 | 4,457 | 1,565 | 2,004 | |
| Earnings per share (EPS)2 | 3.01 | 0.62 | 2.66 | 0.94 | 1.21 | |
| Share price1, 3 | 50.65 | 63.87 | 54.78 | 60.20 | 60.04 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 16.81 | 103.55 | 20.56 | 64.22 | 49.80 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| Abbott Laboratories | 56.47 | 220.29 | 55.16 | 12.83 | 31.30 | |
| AbbVie Inc. | 20.60 | 35.47 | 16.54 | 17.01 | 55.08 | |
| Allergan PLC | — | — | 5.60 | 31.94 | — | |
| Amgen Inc. | 14.01 | 64.06 | 16.03 | 15.95 | 22.96 | |
| Biogen Inc. | 14.79 | 28.83 | 15.41 | 16.67 | 31.27 | |
| Eli Lilly & Co. | 39.13 | — | 32.39 | 33.35 | 33.06 | |
| Gilead Sciences Inc. | 15.26 | 22.75 | 6.83 | 6.75 | 12.85 | |
| Johnson & Johnson | 23.74 | 268.10 | 20.08 | 18.80 | 17.15 | |
| Merck & Co. Inc. | 33.46 | 61.63 | 46.14 | 31.64 | 13.94 | |
| Pfizer Inc. | 21.58 | 9.99 | 28.10 | 26.37 | 23.03 | |
| Regeneron Pharmaceuticals Inc. | 18.17 | 28.99 | 42.64 | 60.50 | 118.44 | |
| Vertex Pharmaceuticals Inc. | 22.59 | 155.08 | — | — | — | |
| Zoetis Inc. | 28.68 | 44.09 | 31.63 | 62.14 | 39.59 | |
| P/E Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 25.26 | 43.06 | 18.12 | 19.56 | — | |
| P/E Ratio, Industry | ||||||
| Health Care | 26.35 | 39.10 | 19.92 | 21.00 | — | |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 Data adjusted for splits and stock dividends.
2 2018 Calculation
EPS = Net earnings attributable to BMS ÷ No. shares of common stock outstanding
= 4,920,000,000 ÷ 1,632,675,877 = 3.01
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Annual Report.
4 2018 Calculation
P/E ratio = Share price ÷ EPS
= 50.65 ÷ 3.01 = 16.81
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Bristol-Myers Squibb Co.’s P/E ratio increased from 2016 to 2017 but then decreased significantly from 2017 to 2018. |
Price to Operating Profit (P/OP)
Bristol-Myers Squibb Co., historical P/OP calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 1,632,675,877 | 1,632,582,502 | 1,672,715,340 | 1,669,459,090 | 1,662,118,446 | |
| Selected Financial Data (US$) | ||||||
| Operating income (in millions) | 5,118 | 3,612 | 4,630 | 1,890 | 2,591 | |
| Operating profit per share2 | 3.13 | 2.21 | 2.77 | 1.13 | 1.56 | |
| Share price1, 3 | 50.65 | 63.87 | 54.78 | 60.20 | 60.04 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 16.16 | 28.87 | 19.79 | 53.18 | 38.52 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| Abbott Laboratories | 36.64 | 60.88 | 24.25 | 19.80 | 27.50 | |
| AbbVie Inc. | 18.35 | 19.63 | 10.49 | 11.61 | 28.64 | |
| Allergan PLC | — | — | — | — | — | |
| Amgen Inc. | 11.46 | 12.71 | 12.64 | 13.07 | 19.13 | |
| Biogen Inc. | 11.13 | 13.70 | 11.08 | 12.09 | 23.10 | |
| Eli Lilly & Co. | 33.99 | 39.61 | 25.63 | 29.86 | 29.71 | |
| Gilead Sciences Inc. | 10.15 | 7.45 | 5.23 | 5.50 | 10.19 | |
| Johnson & Johnson | 18.34 | 18.94 | 16.09 | 16.50 | 13.36 | |
| Merck & Co. Inc. | 25.08 | 22.58 | 33.62 | 20.29 | 29.30 | |
| Pfizer Inc. | 17.19 | 15.62 | 16.88 | 15.52 | 15.88 | |
| Regeneron Pharmaceuticals Inc. | 17.53 | 16.71 | 28.70 | 30.74 | 49.17 | |
| Vertex Pharmaceuticals Inc. | 74.57 | 331.55 | 2,143.58 | — | — | |
| Zoetis Inc. | 22.59 | 22.33 | 18.65 | 28.09 | 24.45 | |
| P/OP Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 20.43 | 20.04 | 16.41 | 16.74 | — | |
| P/OP Ratio, Industry | ||||||
| Health Care | 20.56 | 20.22 | 16.86 | 17.06 | — | |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 Data adjusted for splits and stock dividends.
2 2018 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= 5,118,000,000 ÷ 1,632,675,877 = 3.13
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Annual Report.
4 2018 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 50.65 ÷ 3.13 = 16.16
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Bristol-Myers Squibb Co.’s P/OP ratio increased from 2016 to 2017 but then decreased significantly from 2017 to 2018. |
Price to Sales (P/S)
Bristol-Myers Squibb Co., historical P/S calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 1,632,675,877 | 1,632,582,502 | 1,672,715,340 | 1,669,459,090 | 1,662,118,446 | |
| Selected Financial Data (US$) | ||||||
| Revenues (in millions) | 22,561 | 20,776 | 19,427 | 16,560 | 15,879 | |
| Sales per share2 | 13.82 | 12.73 | 11.61 | 9.92 | 9.55 | |
| Share price1, 3 | 50.65 | 63.87 | 54.78 | 60.20 | 60.04 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 3.67 | 5.02 | 4.72 | 6.07 | 6.28 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| Abbott Laboratories | 4.37 | 3.84 | 3.70 | 2.78 | 3.53 | |
| AbbVie Inc. | 3.58 | 6.67 | 3.84 | 3.83 | 4.90 | |
| Allergan PLC | 2.93 | 3.40 | 5.65 | 7.81 | 5.79 | |
| Amgen Inc. | 5.22 | 5.82 | 5.65 | 5.28 | 6.13 | |
| Biogen Inc. | 4.87 | 5.96 | 4.98 | 5.49 | 9.46 | |
| Eli Lilly & Co. | 5.15 | 3.71 | 4.18 | 4.02 | 4.03 | |
| Gilead Sciences Inc. | 3.84 | 4.10 | 3.08 | 3.80 | 6.36 | |
| Johnson & Johnson | 4.45 | 4.56 | 4.62 | 4.13 | 3.77 | |
| Merck & Co. Inc. | 4.92 | 3.68 | 4.54 | 3.56 | 3.93 | |
| Pfizer Inc. | 4.49 | 4.05 | 3.84 | 3.76 | 4.24 | |
| Regeneron Pharmaceuticals Inc. | 6.62 | 5.92 | 7.86 | 9.38 | 14.62 | |
| Vertex Pharmaceuticals Inc. | 15.54 | 16.42 | 12.51 | 20.38 | 47.41 | |
| Zoetis Inc. | 7.03 | 7.18 | 5.31 | 4.42 | 4.82 | |
| P/S Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 4.56 | 4.65 | 4.44 | 4.37 | — | |
| P/S Ratio, Industry | ||||||
| Health Care | 3.49 | 3.53 | 3.27 | 3.28 | — | |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 Data adjusted for splits and stock dividends.
2 2018 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= 22,561,000,000 ÷ 1,632,675,877 = 13.82
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Annual Report.
4 2018 Calculation
P/S ratio = Share price ÷ Sales per share
= 50.65 ÷ 13.82 = 3.67
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Bristol-Myers Squibb Co.’s P/S ratio increased from 2016 to 2017 but then decreased significantly from 2017 to 2018. |
Price to Book Value (P/BV)
Bristol-Myers Squibb Co., historical P/BV calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 1,632,675,877 | 1,632,582,502 | 1,672,715,340 | 1,669,459,090 | 1,662,118,446 | |
| Selected Financial Data (US$) | ||||||
| Total Bristol-Myers Squibb Company shareholders’ equity (in millions) | 14,031 | 11,741 | 16,177 | 14,266 | 14,852 | |
| Book value per share (BVPS)2 | 8.59 | 7.19 | 9.67 | 8.55 | 8.94 | |
| Share price1, 3 | 50.65 | 63.87 | 54.78 | 60.20 | 60.04 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 5.89 | 8.88 | 5.66 | 7.04 | 6.72 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| Abbott Laboratories | 4.38 | 3.40 | 3.76 | 2.68 | 3.32 | |
| AbbVie Inc. | — | 36.95 | 21.24 | 22.17 | 56.09 | |
| Allergan PLC | 0.71 | 0.73 | 1.08 | 1.54 | 2.67 | |
| Amgen Inc. | 9.41 | 5.02 | 4.14 | 3.94 | 4.59 | |
| Biogen Inc. | 5.03 | 5.80 | 4.70 | 6.31 | 8.49 | |
| Eli Lilly & Co. | 12.87 | 7.33 | 6.33 | 5.51 | 5.14 | |
| Gilead Sciences Inc. | 3.89 | 5.15 | 4.88 | 6.59 | 10.08 | |
| Johnson & Johnson | 6.08 | 5.79 | 4.72 | 4.07 | 4.01 | |
| Merck & Co. Inc. | 7.79 | 4.30 | 4.51 | 3.15 | 3.42 | |
| Pfizer Inc. | 3.80 | 2.98 | 3.40 | 2.84 | 2.95 | |
| Regeneron Pharmaceuticals Inc. | 5.07 | 5.66 | 8.58 | 10.53 | 16.22 | |
| Vertex Pharmaceuticals Inc. | 10.68 | 20.14 | 18.42 | 22.38 | 25.60 | |
| Zoetis Inc. | 18.74 | 21.52 | 17.46 | 19.72 | 17.61 | |
| P/BV Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 5.31 | 4.53 | 4.09 | 3.83 | — | |
| P/BV Ratio, Industry | ||||||
| Health Care | 4.86 | 4.34 | 3.89 | 3.56 | — | |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 Data adjusted for splits and stock dividends.
2 2018 Calculation
BVPS = Total Bristol-Myers Squibb Company shareholders’ equity ÷ No. shares of common stock outstanding
= 14,031,000,000 ÷ 1,632,675,877 = 8.59
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Annual Report.
4 2018 Calculation
P/BV ratio = Share price ÷ BVPS
= 50.65 ÷ 8.59 = 5.89
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Bristol-Myers Squibb Co.’s P/BV ratio increased from 2016 to 2017 but then slightly decreased from 2017 to 2018 not reaching 2016 level. |